These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 31322508)
1. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS. Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508 [TBL] [Abstract][Full Text] [Related]
2. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663 [TBL] [Abstract][Full Text] [Related]
4. Tubal origin of 'ovarian' low-grade serous carcinoma. Li J; Abushahin N; Pang S; Xiang L; Chambers SK; Fadare O; Kong B; Zheng W Mod Pathol; 2011 Nov; 24(11):1488-99. PubMed ID: 21701538 [TBL] [Abstract][Full Text] [Related]
5. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor. Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472 [TBL] [Abstract][Full Text] [Related]
6. Cell polarity reversal in ovarian low-grade serous carcinomas and micropapillary serous borderline tumours: immunohistochemical observations. Hui Y; Ou JJ; Sung CJ; Lawrence WD; Quddus MR Histopathology; 2016 Nov; 69(5):892-894. PubMed ID: 27271798 [No Abstract] [Full Text] [Related]
7. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Boyd C; McCluggage WG Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603 [TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas. Halperin R; Zehavi S; Dar P; Habler L; Hadas E; Bukovsky I; Schneider D Eur J Gynaecol Oncol; 2001; 22(4):292-6. PubMed ID: 11695812 [TBL] [Abstract][Full Text] [Related]
9. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
10. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor. Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113 [TBL] [Abstract][Full Text] [Related]
11. Apoptotic and proliferative activity in ovarian benign, borderline and malignant tumors. Liu A; Chen L; Ngan HY; Khoo US; Zhao Y; Cheung AN Chin Med Sci J; 2002 Jun; 17(2):106-11. PubMed ID: 12906164 [TBL] [Abstract][Full Text] [Related]
12. [Expression and promotor methylation of p73 gene in ovarian epithelial tumors]. Zhang YL; Guo XR; Shen DH; Cheng YX; Liang XD; Chen YX; Wang Y Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):33-8. PubMed ID: 22455848 [TBL] [Abstract][Full Text] [Related]
13. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours. Tan Y; Sinniah R; Bay BH; Singh G J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489 [TBL] [Abstract][Full Text] [Related]
14. Low-grade Serous Neoplasia of the Female Genital Tract. Folkins AK; Longacre TA Surg Pathol Clin; 2019 Jun; 12(2):481-513. PubMed ID: 31097112 [TBL] [Abstract][Full Text] [Related]
15. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma. Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433 [TBL] [Abstract][Full Text] [Related]
18. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma]. Xiang L; Li J; Wang LJ; Zheng WX; Kong BH Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of DEK overexpression in serous ovarian tumors. Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407 [TBL] [Abstract][Full Text] [Related]
20. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer. Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]